Mark Erlander
CIK 1651537 · Chief Executive Officer · last filed 2025-03-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$20.0K
Companies
3
Total Filings
31
Lifetime Open-Market Net
$44.7K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRDF | Chief Executive Officer | 24,481 | $0.82 | $20.0K | $34.3K | 10 | 2025-03-13 |
| Cardiff Oncology, Inc. (TROV) Delisted | Chief Scientific Officer | 6,231 | — | — | $0 | 16 | 2020-01-03 |
| Cardiff Oncology, Inc. (TROVW) Delisted | Chief Scientific Officer | 55,000 | — | — | $10.4K | 5 | 2017-04-10 |
Recent Filings · Page 2 of 4
31 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-01-03 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +698 | $0 | EDGAR |
| 2020-01-03 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +145 | $0 | EDGAR |
| 2019-10-03 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +784 | $0 | EDGAR |
| 2019-07-03 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +789 | $0 | EDGAR |
| 2019-06-24 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-04-03 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +791 | $0 | EDGAR |
| 2019-01-04 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +865 | $0 | EDGAR |
| 2019-01-04 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +4,465 | $0 | EDGAR |
| 2018-10-03 | Cardiff Oncology, Inc. (TROV) Delisted | Mixed | +4,769 | $0 | EDGAR |
| 2018-07-26 | Cardiff Oncology, Inc. (TROV) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.